|Bid||0.6700 x 0|
|Ask||0.6800 x 0|
|Day's Range||0.6500 - 0.6700|
|52 Week Range||0.5700 - 1.3800|
|Beta (5Y Monthly)||2.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 22, 2022 - Feb. 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.87|
Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that Hesperco, its unique flavonoid formulation approved by Health Canada for immune support, is now available for sale in approximately 300 stores under the Loblaw's banners including Loblaws, Dominion, Zehrs, Fortinio's, Your Independent Grocer and Superstore.
Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, is proud to announce a major milestone for its two innovative Asthma therapies ; Atectura Breezhaler and Enerzair Breezehaler are now reimbursed by the Quebec RAMQ, and by Nova Scotia Minister of Health, effective December 15, 2021 and December 2, 2021 respectively. The listings now appear on the Quebec List of Medications and the Nova Scotia Drug Formulary.
Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, is pleased to announce it has closed its previously announced upsized bought deal private placement (the "Offering") of $15.0 million aggregate principal amount of 12.0% convertible unsecured debentures (the "Debentures") of the Company due December 31, 2024 (the "Maturity Date") at a price of $1,000 (the "Offering Price") per Debenture, through a syndicate of underwriters led by De